The Prevalence and Reproductive Outcome of Infertile Women With Genital Tuberculosis

Phase

N/A

Condition

Infertility

Hiv

Lung Disease

Treatment

N/A

Clinical Study ID

NCT05311423

KY2021-840

Ages 20-43
Female

Study Summary

Female genital tuberculosis infection (FGTB) is an important cause of female infertility in TB-endemic areas. The pregnancy rate of assisted reproductive treatment (ART) in the infertile women with FGTB is still unsatisfied even after receiving standard anti-tuberculosis treatment. Moreover, recent years have witnessed an alarming increase in reports of FGTB-related maternal and neonatal complications after fertility treatments. These underscore that timely detection and treatment of FGTB before ART hold benefit for the mother and child.

Eligibility Criteria

Inclusion

Inclusion Criteria:

1. Female, aged ≥20 years and <43 years old;
1. In line with conventional assisted reproduction indications;
1. Meet any of the following:

with tuberculosis infection history;
with a history of close contact to tuberculosis patients;
exact positive IGRA results in the past or chest imaging indicated a past historyof pulmonary tuberculosis;
suspected symptoms of tuberculosis, including fever, night sweats, fatigue, coughand sputum;
suspected symptoms of genital tuberculosis, including lower abdominal pain,abnormal menstruation, fallopian tube stenosis, obstruction, thickening, beadingchanges, uterine cavity adhesions, deformation, pelvic adhesions, etc.;

1. Voluntarily join the study and sign the informed consent

Exclusion

Exclusion Criteria:

1. Co-infection with HIV;
1. Chromosomal abnormalities;
1. suspected genital tuberculosis infection symptoms (participants meet inclusioncriteria 3)e in Inclusion Criteria) known to be caused only by factors part fromtuberculosis, such as endocrine factors, history of ectopic pregnancy, history ofuterine curettage, chronic pelvic inflammatory disease, endometriosis, malignanttumors, etc.;
1. There are other serious physical or mental illnesses that are not suitable forselection;
1. Participate in other clinical studies that would affect this study at the sametime.

Study Design

December 01, 2021

August 01, 2023

Study Description

This project aims to recruit infertile female with high risk of tuberculosis infecton who need assisted reproductive treatment in multiple reproductive centers. The infertility-related medical history and laboratory examination results were recorded according to clinical routine, and other essential information such as tuberculosis symptoms, tuberculosis-related history and other health conditions were also recorded, and the pregnancy outcomes of these patients were followed up.

According to the results of clinical screening, they were divided into four cohorts: non-tuberculosis (non-TB) group, latent tuberculosis infection (LTBI) group, subclinical genital tuberculosis infection (SGTB) group and female genital tuberculosis infection (FGTB) group.

Non-TB group: QuantiFERON-TB test (QFT) negative, continue assisted reproductive treatment; LTBI group: QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, acid-fast bacilli (AFB) microscopy, Mycobacterium tuberculosis (Mtb) culture, or GeneXpert MTB/RIF Ultra test results. Then assisted reproductive treatment can be continued, but follow-up for tuberculosis-related symptoms is required; SGTB group: QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, AFB microscopy, Mtb culture, but GeneXpert MTB/RIF Ultra positive test results. They are recommended to receive 6-month first-line standard anti-tuberculosis treatment (ATT) regimen; FGTB group: QFT positive. Excluded active pulmonary tuberculosis, regardless of GeneXpert MTB/RIF Ultra results, at least one of these test results, including endometrial histopathologiy, AFB microscopy, Mtb culture is positive, they will receive 6-month ATT.

Patients diagnosed with SGTB and FGTB will receive 6-month first-line standard ATT before ART, and follow up their anti-tuberculosis drug-related adverse reactions (TB-ARs) according to clinical routine to prevent the occurrence of grade 3-4 adverse drug reactions.

All cohorts will be followed up for pregnancy outcomes after entering the assisted reproduction cycle, and the pregnancy outcomes of all subjects after the first assisted reproduction after enrollment were recorded. Follow-up nodes included the 2nd, 4th, 10th weeks and 37th weeks of gestation. Follow-up content includes pregnancy status. Follow-up subjects will be terminated when adverse pregnancy outcomes such as ectopic pregnancy and miscarriage occurred; follow-up of pregnant participants will be extended to 2 weeks postpartum. Participants from the SGTB or FGTB group achieve pregnant naturally after drug withdrawal, the follow-up of the natural pregnancy outcome will be started as well.

Connect with a study center

Shanghai First Maternity and Infant Hospital
Shanghai, Shanghai 200051
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.